INDV - Indivior PLC Ordinary Shares

INDV - Indivior PLC Ordinary Shares

https://www.indivior.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

What Makes Indivior PLC ( INDV ) a Strong Momentum Stock: Buy Now?

Zacks Commentary • 4 days, 23 hours ago • score: 0.44

Does Indivior PLC (INDV) have what it takes to be a top stock pick for momentum investors? Let's find out.

This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Almonty Indus ( NASDAQ:ALM ) , Adagene ( NASDAQ:ADAG )

Benzinga • 1 month, 1 week ago • score: 0.14

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

All You Need to Know About Indivior ( INDV ) Rating Upgrade to Strong Buy

Zacks Commentary • 1 month, 1 week ago • score: 0.37

Indivior (INDV) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Best Momentum Stock to Buy for August 5th

Zacks Commentary • 1 month, 1 week ago • score: 0.13

FFIV, INDV and NVT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 5, 2025.

New Strong Buy Stocks for August 5th

Zacks Commentary • 1 month, 1 week ago • score: 0.13

ARMN, QUAD, NVST, INDV and BJRI have been added to the Zacks Rank #1 (Strong Buy) List on August 5, 2025.

Indivior ( INDV ) Q2 EPS Jumps 104%

Motley Fool • 1 month, 2 weeks ago • score: 0.13

Indivior ( NASDAQ:INDV ) , a global pharmaceutical company known for its treatments for opioid use disorder ( OUD ) , reported results on July 31, 2025. The main news was a sharp outperformance compared to analyst estimates, with non-GAAP EPS of $0.51 beating the $0.25 consensus.

Indivior PLC ( INDV ) Tops Q2 Earnings and Revenue Estimates

Zacks Commentary • 1 month, 2 weeks ago • score: 0.21

Indivior (INDV) delivered earnings and revenue surprises of +96.15% and +22.05%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Indivior PLC, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company is headquartered in North Chesterfield, Virginia.

52W High

$25.00

52W Low

$7.33

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

1.06

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

30.84

Forward P/E (<15 better)

13.18

EV/EBITDA (<8 favorable)

11.39

EV/Revenue (<3 favorable)

2.53

P/S (TTM) (<3 favorable)

2.66

P/B (<3 favorable)

145.25

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

3.88%

Institutions (25–75% balanced)

88.99%

Shares Outstanding

124,770,000

Float

89,803,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

2016-06-16

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

1,173,000,000

Gross Profit (TTM)

985,000,000

EPS (TTM)

0.81

Profit Margin (>10% good)

0.05%

Operating Margin (TTM) (higher better)

0.24%

ROE (TTM) (>15% strong)

0.12%

EPS YoY (Quarterly) (>10% good)

-0.16

Revenue YoY (Quarterly) (>8% good)

0.01

Momentum

Bearish momentum

Value

1.5974

Previous

1.6379

Trend

Falling

Signal Cross

No cross

As of

Sep. 05, 2025